Morphic Therapeutic has raised $80.0 million in new investment capital. The company is focused on developing oral integrin therapies for patients suffering from immunological, fibrotic, neoplastic, and vascular diseases. Integrins represent a critical receptor family that has been an important drug target for decades, leading to the successful development of six injectable therapies approved for conditions such as multiple sclerosis, ulcerative colitis, and Crohn's disease.
Despite the commercial success of these injectable treatments, integrins have historically proven challenging to target with small molecule drugs. Morphic Therapeutic aims to overcome this hurdle, building on a three-decade quest initiated by its scientific founder, Tim Springer, who first discovered the integrin receptor family in the 1980s. The company's approach seeks to unlock the potential of integrins for oral administration, offering a new paradigm for patient treatment.
This funding round underscores investor confidence in Morphic Therapeutic's platform and its potential to deliver novel oral therapies. The $80.0 million in capital will be deployed to advance the company's pipeline of oral integrin programs, support ongoing research and development efforts, and expand its operational capabilities. This investment is crucial for progressing its innovative drug candidates through preclinical and clinical stages.
Morphic Therapeutic is poised to continue its work in transforming the treatment landscape for a range of serious diseases. The company's strategic focus on developing accessible oral integrin therapies positions it for significant growth as it strives to bring these much-needed treatments to patients.
